Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: The Prostate 2022, 82(14):1406-1412. DOI: 10.1002/pros.24414
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2023
- Urheber
-
Hartrampf, Philipp E.
Weinzierl, Franz-Xaver
Seitz, Anna Katharina
Kübler, Hubert
Essler, Markus
Buck, Andreas K.
Wolf, Herta
Bundschuh, Ralph A.
- DOI
-
10.1002/pros.24414
- URN
-
urn:nbn:de:bvb:20-opus-318766
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hartrampf, Philipp E.
- Weinzierl, Franz-Xaver
- Seitz, Anna Katharina
- Kübler, Hubert
- Essler, Markus
- Buck, Andreas K.
- Wolf, Herta
- Bundschuh, Ralph A.
- Universität Würzburg
Entstanden
- 2023
Ähnliche Objekte (12)
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
Prostate-specific antigen increase after urethral catheterisation: fact or myth
Biological Half-Life of Prostate-Specific Antigen after Radical Prostatectomy
Some Analytical Considerations on the Measurement of Prostate-Specific Antigen
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
Prostate-specific antigen increase after urethral catheterisation: fact or myth
Biological Half-Life of Prostate-Specific Antigen after Radical Prostatectomy
Some Analytical Considerations on the Measurement of Prostate-Specific Antigen
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
Prostate-specific antigen increase after urethral catheterisation: fact or myth
Biological Half-Life of Prostate-Specific Antigen after Radical Prostatectomy